Telomerase activity: An attractive target for cancer therapeutics

doi:10.5497/wjp.v3.i4.86

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9561)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

728

WORD

437

HTML

6356

Figures (1-3)

281

Sum=7802

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

858

Download

901

Sum=1759

Dec 9, 2014 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Dec 9, 2014; 3(4): 86-96
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.86

Full Size Figure Download Figure

Figure 2 Telomeres an telomerase complex. (TTAGG)n sequences form a 3’-overhang on the 3’ end of chromosome. Telomerase is composed by hTERT and hTER subunits; hTER is the RNA template for DNA synthesis to add new telomeric TTAGG sequences on 3’-overhang; B: DNA polymerase completes the lagging strand; C: GRN163L sequence complementary. hTERT: Human TElomerase Reverse Transcriptase; hTER: Human TElomerase RNA.

Citation: Picariello L, Grappone C, Polvani S, Galli A. Telomerase activity: An attractive target for cancer therapeutics. World J Pharmacol 2014; 3(4): 86-96
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/86.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.86